Cabot Corp

Cabot Corp(CBT)股票分析

$73.460

-0.823 (-1.12%)收盤時

Loading chart…
最高
75.000
開盤
75.000
成交量加權均價
73.86
成交量
353.40K
市值
5.16B
最低
73.130
成交金額
26.10M
企業價值/稅息折舊攤銷前利潤(TTM)
6.73

Cabot Corporation is a global specialty chemicals and performance materials company. The Company's principal products are reinforcing and specialty carbons, specialty compounds, conductive additives, carbon nanotubes, fumed metal oxides, inkjet colorants and aerogel. It operates through two segments: Reinforcement Materials and Performance Chemicals. Its reinforcing carbon products are used in tires and industrial products. In addition to its reinforcing carbons, it manufactures engineered elastomer composites (E2C) solutions that are composites of reinforcing carbons and rubber made using its patented elastomer composites manufacturing process. Under the Performance Chemicals segment, it designs, manufactures and sells materials that deliver performance in a range of customer applications across the automotive, construction, infrastructure, inkjet printing, electronics, and consumer products sectors and in applications related to the generation, transmission and storage of energy.

AI 分析 of Cabot Corp (CBT)

持有

Cabot Corp is currently not a strong buy due to its recent earnings decline and technical indicators. The current price is $74.29, and the RSI is at 31.63, indicating oversold conditions. However, the forward P/E ratio is attractive at 9.94, suggesting potential value. The main risk is the significant drop in Q3 earnings, with net income falling to $6 million from $101 million year-over-year, which raises concerns about profitability.

分析師評級(7)

-9.71% 下跌空間
持有
3 買進
4 持有
0 賣出
目前: 73.46
最低
54.00
平均
66.33
最高
80.00

UBS

2026-10-05

目標價

$86

中性

Truist

2026-08-05

目標價

$100

買進

Mizuho

2026-06-25

目標價

$90

中性

JPMorgan

2026-05-13

目標價

$70

減持

UBS

2026-05-08

目標價

$86

中性

估值指標

Cabot Corp(CBT)目前預期本益比為 9.94,5 年平均預期本益比為 11.16。

預期本益比

合理
5 年均值 P/E
11.16
目前P/E
9.94
高估
12.58
低估
9.74

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
6.96
目前EV/EBITDA
6.73
高估
7.63
低估
6.29

預期股價營收比

合理
5 年均值 P/S
1.05
目前P/S
1.01
高估
1.22
低估
0.88

Alphio AI 對 CBT 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%CBT

$73.88

情境價格

基

基準

基準 · 50%CBT

$69.19

情境價格

悲

悲觀

悲觀 · 25%CBT

$55.14

情境價格

持有 CBT 的大戶

F

Fiduciary Trust Company

+ 持有CBT

+0.68%

3個月報酬率

L

Leeward Investments, LLC

+ 持有CBT

-2.81%

3個月報酬率

E

EARNEST Partners, LLC

+ 持有CBT

-5.52%

3個月報酬率

事件時間軸

2026-09-17 (ET)

09:30:00

Cabot Secures $50M Grant from DOE

2026-09-15 (ET)

09:00:00

Cabot Appoints Steve Delahunt as Interim CFO

2026-08-03 (ET)

17:00:00

Cabot Reports Q3 Revenue of $982M, Beating Expectations

17:00:00

Company Adjusts Fiscal 2026 EPS Guidance to $6.15-$6.45

2026-05-05 (ET)

16:50:00

Cabot Sees FY26 Adjusted EPS $6.00-$6.50

資訊

CBT 常見問題 —— 由 Alphio AI 解答

Cabot Corporation is a global specialty chemicals and performance materials company. The Company's principal products are reinforcing and specialty carbons, specialty compounds, conductive additives, carbon nanotubes, fumed metal oxides, inkjet colorants and aerogel. It operates through two segments: Reinforcement Materials and Performance Chemicals. Its reinforcing carbon products are used in tires and industrial products. In addition to its reinforcing carbons, it manufactures engineered elastomer composites (E2C) solutions that are composites of reinforcing carbons and rubber made using its patented elastomer composites manufacturing process. Under the Performance Chemicals segment, it designs, manufactures and sells materials that deliver performance in a range of customer applications across the automotive, construction, infrastructure, inkjet printing, electronics, and consumer products sectors and in applications related to the generation, transmission and storage of energy. It operates in the Basic Materials sector (MISCELLANEOUS CHEMICAL PRODUCTS industry).

Cabot Corp is currently not a strong buy due to its recent earnings decline and technical indicators. The current price is $74.29, and the RSI is at 31.63, indicating oversold conditions. However, the forward P/E ratio is attractive at 9.94, suggesting potential value. The main risk is the significant drop in Q3 earnings, with net income falling to $6 million from $101 million year-over-year, which raises concerns about profitability.

7 analysts cover CBT: 3 rate it Buy, 4 Hold and 0 Sell. The average price target is 66.33.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易